Which has higher earnings and valuation, CABA or COAG?

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is CABA or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Hemab Therapeutics N/A N/A N/A

Which has stronger earnings & valuation, CABA or XNCR?

Xencor has higher revenue and earnings than Cabaletta Bio. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Xencor $125.58M 14.36 -$91.92M -$2.17 N/A

Is CABA or XNCR more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Xencor -155.59% -28.66% -20.38%

Which has higher earnings & valuation, KLRA or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is KLRA or CABA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Cabaletta Bio N/A -128.27% -95.47%

Cabaletta Bio (CABA) Competitors

$2.22 -0.28 (-11.20%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.20 -0.02 (-0.68%)

As of 06:51 AM Eastern

Compare

CABA vs. COAG, XNCR, KLRA, SEPN, and VIR

Should you buy Cabaletta Bio stock or one of its competitors? Cabaletta Bio's main competitors and comparable companies include Hemab Therapeutics (COAG), Xencor (XNCR), Kailera Therapeutics (KLRA), Septerna (SEPN), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cabaletta Bio compare to Hemab Therapeutics?

Cabaletta Bio (NASDAQ:CABA) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Cabaletta Bio currently has a consensus target price of $15.33, suggesting a potential upside of 590.69%. Hemab Therapeutics has a consensus target price of $51.40, suggesting a potential upside of 39.94%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Cabaletta Bio is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Hemab Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Hemab Therapeutics	N/A	N/A	N/A

In the previous week, Hemab Therapeutics had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 5 mentions for Hemab Therapeutics and 0 mentions for Cabaletta Bio. Hemab Therapeutics' average media sentiment score of 0.15 beat Cabaletta Bio's score of 0.00 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Hemab Therapeutics	Neutral

Summary

Cabaletta Bio beats Hemab Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Cabaletta Bio compare to Xencor?

Cabaletta Bio (NASDAQ:CABA) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Cabaletta Bio presently has a consensus price target of $15.33, indicating a potential upside of 590.69%. Xencor has a consensus price target of $31.13, indicating a potential upside of 28.30%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Xencor has higher revenue and earnings than Cabaletta Bio. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Xencor	$125.58M	14.36	-$91.92M	-$2.17	N/A

Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Xencor	-155.59%	-28.66%	-20.38%

Cabaletta Bio has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market. Comparatively, Xencor has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

In the previous week, Xencor had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 5 mentions for Xencor and 0 mentions for Cabaletta Bio. Xencor's average media sentiment score of 0.17 beat Cabaletta Bio's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Xencor	Neutral

Summary

Cabaletta Bio and Xencor tied by winning 6 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Cabaletta Bio	N/A	-128.27%	-95.47%

In the previous week, Kailera Therapeutics had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 6 mentions for Kailera Therapeutics and 0 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.00 beat Kailera Therapeutics' score of -0.04 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Kailera Therapeutics	Neutral
Cabaletta Bio	Neutral

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 225.59%. Cabaletta Bio has a consensus price target of $15.33, suggesting a potential upside of 590.69%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Summary

Kailera Therapeutics beats Cabaletta Bio on 5 of the 8 factors compared between the two stocks.

How does Cabaletta Bio compare to Septerna?

Cabaletta Bio (NASDAQ:CABA) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Cabaletta Bio has a beta of 3.27, suggesting that its stock price is 227% more volatile than the broader market. Comparatively, Septerna has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market.

Septerna has higher revenue and earnings than Cabaletta Bio. Septerna is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Septerna	$98.88M	18.15	-$48.88M	-$0.54	N/A

Cabaletta Bio has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Septerna	-24.51%	-9.57%	-6.28%

Cabaletta Bio currently has a consensus target price of $15.33, suggesting a potential upside of 590.69%. Septerna has a consensus target price of $52.44, suggesting a potential upside of 36.40%. Given Cabaletta Bio's higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Cabaletta Bio's average media sentiment score of 0.00 equaled Septerna'saverage media sentiment score.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Septerna	Neutral

Summary

Septerna beats Cabaletta Bio on 7 of the 11 factors compared between the two stocks.

How does Cabaletta Bio compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Vir Biotechnology has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market.

Cabaletta Bio has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$302.59M	6.20	-$437.99M	-$1.86	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Vir Biotechnology currently has a consensus price target of $21.57, suggesting a potential upside of 94.51%. Cabaletta Bio has a consensus price target of $15.33, suggesting a potential upside of 590.69%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Vir Biotechnology had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 1 mentions for Vir Biotechnology and 0 mentions for Cabaletta Bio. Vir Biotechnology's average media sentiment score of 1.67 beat Cabaletta Bio's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Vir Biotechnology	Very Positive
Cabaletta Bio	Neutral

65.3% of Vir Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cabaletta Bio has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Cabaletta Bio	N/A	-128.27%	-95.47%

Summary

Vir Biotechnology beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$423.86M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.41	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.91	15.40	10.47	6.32
Net Income	-$167.86M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-13.95%	-1.70%	-0.67%	0.17%
1 Month Performance	-28.39%	-6.17%	-3.17%	-3.27%
1 Year Performance	-10.12%	30.67%	15.14%	5.58%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.2194 of 5 stars	$2.22 -11.2%	$15.33 +590.7%	-8.3%	$423.86M	N/A	N/A	158
COAG Hemab Therapeutics	3.2104 of 5 stars	$40.47 +2.7%	$51.40 +27.0%	N/A	$1.84B	N/A	N/A	59
XNCR Xencor	2.2371 of 5 stars	$24.53 +0.5%	$31.86 +29.9%	+135.1%	$1.81B	$125.58M	N/A	260	Analyst Forecast
KLRA Kailera Therapeutics	3.1624 of 5 stars	$13.75 -1.4%	$42.75 +210.9%	N/A	$1.81B	N/A	N/A	145
SEPN Septerna	2.916 of 5 stars	$39.55 +2.7%	$52.44 +32.6%	+139.4%	$1.80B	$45.95M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. COAG, XNCR, KLRA, SEPN, and VIR

How does Cabaletta Bio compare to Hemab Therapeutics?

Summary

How does Cabaletta Bio compare to Xencor?

Summary

How does Cabaletta Bio compare to Kailera Therapeutics?

Summary

How does Cabaletta Bio compare to Septerna?

Summary

How does Cabaletta Bio compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. COAG, XNCR, KLRA, SEPN, and VIR

How does Cabaletta Bio compare to Hemab Therapeutics?

Which has higher earnings and valuation, CABA or COAG?

Do analysts recommend CABA or COAG?

Is CABA or COAG more profitable?

Does the media prefer CABA or COAG?

Summary

How does Cabaletta Bio compare to Xencor?

Do analysts rate CABA or XNCR?

Which has stronger earnings & valuation, CABA or XNCR?

Is CABA or XNCR more profitable?

Which has more risk & volatility, CABA or XNCR?

Does the media favor CABA or XNCR?

Summary

How does Cabaletta Bio compare to Kailera Therapeutics?

Is KLRA or CABA more profitable?

Does the media prefer KLRA or CABA?

Do analysts rate KLRA or CABA?

Which has higher earnings & valuation, KLRA or CABA?

Summary

How does Cabaletta Bio compare to Septerna?

Which has more risk & volatility, CABA or SEPN?

Which has higher earnings & valuation, CABA or SEPN?

Is CABA or SEPN more profitable?

Do analysts recommend CABA or SEPN?

Does the media prefer CABA or SEPN?

Summary

How does Cabaletta Bio compare to Vir Biotechnology?

Which has more volatility and risk, VIR or CABA?

Which has preferable earnings & valuation, VIR or CABA?

Do analysts prefer VIR or CABA?

Does the media refer more to VIR or CABA?

Do institutionals & insiders believe in VIR or CABA?

Is VIR or CABA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools